Apixaban Study Halted - But It May Not Cause Much Damage To The Program
This article was originally published in The Pink Sheet Daily
Executive Summary
The APPRAISE-2 trial was stopped due to excess bleeding. But the study tested the drug as an add-on treatment in a high-risk population and in a marginal indication for the anticoagulant.
You may also be interested in...
Final APPRAISE-al: Trial Report Argues Against Anticoagulant/Antiplatelet Combos In ACS
NEJM article points to much higher bleeding with no compensatory efficacy in failed APPRAISE-2 add-on trial with apixaban.
Final APPRAISE-al: Trial Report Argues Against Anticoagulant/Antiplatelet Combos In ACS
NEJM article points to much higher bleeding with no compensatory efficacy in failed APPRAISE-2 add-on trial with apixaban.
Bayer/J&J Attempt At New Lands For Xarelto Backfires With MAGELLAN
Ability of novel anticoagulants to capture an extra indication in acutely ill patients currently treated with blockbuster Lovenox is now in doubt.